PHASE I STUDY OF CABAZITAXEL IN PEDIATRIC PATIENTS WITH RELAPSED OR REFRACTORY SOLID TUMORS: A POETIC GROUP STUDY

被引：0
|
作者：
Manley, P. [1 ]
Trippett, T. [2 ]
Smith, A. [3 ]
Macy, M. [4 ]
Leary, S. [5 ,6 ]
Boklan, J. [7 ]
Cohen, K. [8 ]
Shen, L. [9 ]
Herzog, C. [10 ]
Veyrat-Follet, C. [11 ]
Zhang, J. [12 ]
Chi, S. [1 ]
机构：
[1] Dana Farber Canc Inst, Pediat Oncol, Boston, MA 02115 USA
[2] Mem Sloan Kettering Canc Ctr, Pediat Hematol Oncol, New York, NY 10021 USA
[3] Arnold Palmer Med Ctr, Pediat Hematol Oncol, Orlando, FL USA
[4] Univ Colorado, Childrens Hosp Colorado, Pediat Hematol Oncol, Aurora, CO USA
[5] Seattle Childrens Univ Washington, Seattle, WA USA
[6] Fred Hutchinson Canc Res Ctr, Pediat Hematol Oncol, Seattle, WA 98104 USA
[7] Phoenix Childrens Hosp, Pediat Hematol Oncol, Phoenix, AZ USA
[8] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Pediat Hematol Oncol, Baltimore, MD USA
[9] Sanofi US, Sanofi Oncol, Bridgewater, MA USA
[10] Univ Texas MD Anderson Canc Ctr, Pediat Hematol Oncol, Houston, TX 77030 USA
[11] Sanofi, Drug Disposit Disposit Safety & Anim Res Dept, Vitry Sur Seine, France
[12] Sanofi, Sanofi Oncol, Cambridge, MA USA
来源：
PEDIATRIC BLOOD & CANCER | 2015年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O-049
引用
收藏
页码：S157 / S158
页数：2
相关论文
共 50 条
  • [21] A phase I study of cetuximab and irinotecan in pediatric patients (pts) with refractory solid tumors
    Trippett, T. M.
    Kuttesch, J.
    Herzog, C.
    Boklan, J.
    Bagatell, R.
    Hunger, S.
    Arceci, R.
    Lu, H.
    Langer, C.
    Gore, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [22] Phase I Study of Vinblastine and Sirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
    Morgenstern, Daniel A.
    Marzouki, Monia
    Bartels, Ute
    Irwin, Meredith S.
    Sholler, Giselle L. S.
    Gammon, Janet
    Yankanah, Rosanna
    Wu, Bing
    Samson, Yvan
    Baruchel, Sylvain
    PEDIATRIC BLOOD & CANCER, 2014, 61 (01) : 128 - 133
  • [23] Phase I study of gemcitabine, docetaxel and imatinib in refractory and relapsed solid tumors
    Biren Saraiya
    Rashmi Chugh
    Vassiliki Karantza
    Janice Mehnert
    Rebecca A. Moss
    Nelli Savkina
    Mark N. Stein
    Laurence H. Baker
    Thomas Chenevert
    Elizabeth A. Poplin
    Investigational New Drugs, 2012, 30 : 258 - 265
  • [24] Phase I study of gemcitabine, docetaxel and imatinib in refractory and relapsed solid tumors
    Saraiya, Biren
    Chugh, Rashmi
    Karantza, Vassiliki
    Mehnert, Janice
    Moss, Rebecca A.
    Savkina, Nelli
    Stein, Mark N.
    Baker, Laurence H.
    Chenevert, Thomas
    Poplin, Elizabeth A.
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (01) : 258 - 265
  • [25] Phase I study of gemcitabine, docetaxel, and imatinib in refractory and relapsed solid tumors
    Saraiya, B.
    Karantza-Wadsworth, V.
    Stein, M. N.
    Chugh, R.
    Mehnert, J.
    Moss, R.
    Lin, Y.
    Poplin, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [26] Phase I study of weekly oxaliplatin in relapsed or refractory pediatric solid malignancies
    Geoerger, Birgit
    Doz, Francois
    Gentet, Jean-Claude
    Mayer, Michele
    Landman-Parker, Judith
    Pichon, Fabienne
    Chastagner, Pascal
    Rubie, Herve
    Frappaz, Didier
    Le Bouil, Anne
    Gupta, Sunil
    Vassal, Gilles
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (27) : 4394 - 4400
  • [27] A phase I/II study of atezolizumab in pediatric and young adult patients with refractory/relapsed solid tumors (iMATRIX-Atezolizumab).
    Geoerger, Birgit
    Karski, Erin E.
    Zwaan, Michel
    Casanova, Michela
    Marshall, Lynley V.
    DuBois, Steven G.
    Kowgier, Matthew
    Tagen, Michael
    Kwan, Antonia
    Das-Thakur, Meghna
    Trippett, Tanya Maria
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [28] A Phase I/II Study of Atezolizumab in Pediatric and Young Adult Patients with Refractory/Relapsed Solid Tumors (Imatrix-Atezolizumab)
    Trippett, T.
    Rossato, G.
    Langevin, A. M.
    Michon, J.
    Frappaz, D.
    Locatelli, F.
    Kowgier, M.
    Tagen, M.
    Kwan, A.
    Das Thakur, M.
    Geoerger, B.
    PEDIATRIC BLOOD & CANCER, 2017, 64 : S346 - S346
  • [29] A phase I study of 17-AAG in relapsed/refractory pediatric patients with solid tumors: A Children's Oncology Groups study.
    Weigel, B.
    Blaney, S.
    Kersey, J.
    Bagatell, R.
    Ivy, S. P.
    Whitesell, L.
    Krailo, M.
    Reid, J.
    Ames, M.
    Adamson, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 506S - 506S
  • [30] Phase I clinical study of oral olaparib in pediatric patients with refractory solid tumors: study protocol
    Takagi, Masatoshi
    Ogawa, Chitose
    Aoki-Nogami, Yuki
    Iehara, Tomoko
    Ishibashi, Eri
    Imai, Minoru
    Kihara, Tetsuro
    Nobori, Kiyoshi
    Hasebe, Kazuhisa
    Mizutani, Shuki
    Kimura, Toshimi
    Nagata, Masashi
    Yasuhara, Masato
    Yoshimura, Kenichi
    Yorozu, Pariko
    Hosoi, Hajime
    Koike, Ryuji
    BMC PEDIATRICS, 2019, 19 (1)
12345